Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK of MK-3866 in Renal Impairment
NCT03259087Phase 1Completed
- Sponsor
- Merck & Co.
- Start
- Sep 2017
- Primary completion
- Jan 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of MK-3866 in bacterial infection (5 arms), sponsored by Merck & Co. Primary endpoints: Area Under the Plasma Concentration-time Curve From Time Zero to Infinity at 72 hours, Area Under the Plasma Concentration-time Curve From Time Zero to Last Quantifiable Sample at 72 hours and 7 more. Started Sep 2017; status: completed.
02
Drugs
MK-3866
03
Conditions
bacterial infection
Beyond the preview
Go deeper on NCT03259087.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03259087.